|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 301 | Herpes Simplex Virus 2 Recombinants as AIDS Vaccine Vectors
W. T. Lucas1, C. G. Murphy1, R. C. Desrosiers2, G. N. Pavlakis3, and D. M. Knipe*1 1Harvard Med. Sch., Boston, MA, USA; 2New England Regional Primate Res. Ctr., Southborough, MA, USA; and 3NCI-FCRDC, Frederick, MD< USA |
| 302 | Helper Virus-Free Herpes Simplex Virus-1 (HSV-1) Amplicon Vectors Expressing HIV-1 gp120 Elicit Potent Cellular and Humoral Immune Responses
P. K. Hocknell1, R. Wiley1, X. Wang1, W. J. Bowers1, T. G. Evans2, T. Hanke3, H. J. Federoff1, and S. Dewhurst*1 1Univ. of Rochester, NY, USA; 2Univ. of California-Davis, USA; and 3Oxford Univ., UK |
| 303 | Preclinical Evaluation of Gene-Delivery-Based HIV-1 Vaccines in Nonhuman Primates
D. R. Casimiro*, T. Fu, L. Chen, R. Evans, X. Liang, A. Bett, R. Youil, D. Kaslow, D. Volkin, M. Davies, W. Hurni, P. Keller, E. Emini, and J. W. Shiver Merck Res. Labs, West Point, PA, USA |
| 304 | HIV-1-Specific Immunity after Genetic Immunization Is Enhanced by Modification of Gag and Pol Expression
Y. Huang*, W. Kong, and G. J. Nabel Vaccine Res. Ctr., NIAID, NIH, Bethesda, MD, USA |
| 305 | The Multi-Epitope Approach to Development of HIV Vaccines
M. Newman*, B. Livingston, D. McKinney, R. Chesnut, and A. Sette Epimmune Inc., San Diego, CA, USA |
| 306 | Novel HIV-1 gp160 Proteoliposomes as Antigens and Immunogens
C. Grundner*1, T. Mirzabekov1,2, J. Sodroski1-3, and R. Wyatt1,2 1Dana-Farber Cancer Inst., Boston, MA, USA; 2Harvard Med. Sch., Boston, MA, USA; and 3Harvard Sch. of Publ. Hlth., Boston, MA, USA |
| 307 | A Glycoprotein-Deficient Rhabdovirus Expressing HIV-1 gp160 Mimics an HIV-1-Like Tropism: Indication for a Novel HIV-1 Vaccine Approach
H. D. Foley1, J. McGettigan1, C. A. Siler1, J. Orenstein2, R. J. Pomerantz1, and M. J. Schnell*1 1Thomas Jefferson Univ., Philadelphia, PA, USA and 2George Washington Univ. Med. Ctr., Washington, DC, USA |
| 308 | Prime-Boost Vaccination for Mucosal Immune Responses of High Avidity
A. J. Ramsay*1, M. Estcourt2, I. Ramshaw2, D. Boyle3, and C. Ranasinghe1 1Ctr. for Biomolecular Vaccine Technology, Univ. of Newcastle, NSW, Australia; 2John Curtin Sch. of Med. Res., Canberra, Australia; and 3CSIRO Australian Animal Hlth. Lab., Geelong, Australia |
| 309 | Memory Responses Are Present in Mucosal and Systemic Compartments after Mucosal (Intranasal) Immunization with Nonreplicating Antigen
S. E. Pacheco*, M. C. Hart, and P. R. Rogers Baylor Coll. of Med., Houston, TX |
| 310 | Combinatorial Libraries of Chimeric Human Rhinoviruses Displaying HIV-1 Immunogens in Diverse Conformations
G. Arnold*1,2, E. Bayman1,2, C. Tu1,3, X. Ma1,2, P. Velasco1,4, S. Geisler1,2, D. Montefiori5, and E. Arnold1 1Ctr. for Advanced Biotechnology and Med., New Brunswick, NJ, USA; 2Rutgers Univ., New Brunswick, NJ, USA; 3Changchun Univ. of Agricultural and Animal Sci., China; 4Univ. of Med. and Dentistry of New Jersey, Piscataway, USA; and 5Duke Univ. Med. Ctr., Durham, NC, USA |
| 311 | Enhanced Potency RNA Optimized HIV-1 Plasmid Vaccines Encoding Engineered B7 Costimulatory Molecules or IL-15
J. Boyer1, S. Kudchodkar1, M. Agadjanian7, J. Im-Sin1, D. Zhang1, J. Kim2, J. Eldridge4, Z. Israel4, G. Pavlakis5, R. Sekaly6, and D. B. Weiner*1 1Univ. of Pennsylvania, Philadelphia, USA; 2Viral Genomix, Philadelphia, PA, USA; 3St. Christopher’s Hosp. for Children, Philadelphia, PA, USA; 4Wyeth Vaccines, Pearl River, NY, USA; 5NCI-FCRF, Frederick, MD, USA; 6Univ. of Montreal, Quebec, Canada; and 7IMM, Los Angeles, CA, USA |
| 312 | HIV-1 Gag DNA Vaccine Chimera with Expression and Adjuvant Properties of the Lysosomal-Associated Membrane Protein (LAMP) and Dendritic Cell Multi-Lectin Receptor (DC-MLR) in an AAV-ITR Plasmid Vector
Y. Lu*, P. R. Chikhlikar, I. C. Leao, J. T. August, and E. T. A. Marques, Jr. The Johns Hopkins Sch. of Med., Baltimore, MD, USA |